Celltrion Pharm, Inc. engages in the manufacture and sale of pharmaceuticals. Its products are categorized into the following: the group of medicine effect, biosimilars and over-the-counter (OTC) drug. The group of medicine effect includes hepatotonics, hepatotonics and anti-inflammatory drugs, antihistamine, respiratory apparatus drugs, circulatory system drug, digestives and stomachics drug, hormone and metabolic disease drugs, antibiotics and antimycotic, nutrientia and tonic, immunology, oncology, and the other drugs. The products of OTC drugs include alcetin tab, alchipil tab, anola tab, araphen tab, ascit granule, caldip tab, celltrion aceclofenac tab, celltrion atenolol tab, celltrion cefadroxil cap, celltrion diclofenac inj, celltrion domperidone tab, celltrion famotidine tab, and ceparo cap. The company was founded on November 17, 2000 and is headquartered in Cheongju, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company